CL2017002059A1 - Compuestos 4- sustitutos de benzoxaborol y uso de los mismos - Google Patents

Compuestos 4- sustitutos de benzoxaborol y uso de los mismos

Info

Publication number
CL2017002059A1
CL2017002059A1 CL2017002059A CL2017002059A CL2017002059A1 CL 2017002059 A1 CL2017002059 A1 CL 2017002059A1 CL 2017002059 A CL2017002059 A CL 2017002059A CL 2017002059 A CL2017002059 A CL 2017002059A CL 2017002059 A1 CL2017002059 A1 CL 2017002059A1
Authority
CL
Chile
Prior art keywords
compounds
ch2c
benzoxaborol
substitutes
h2ch3
Prior art date
Application number
CL2017002059A
Other languages
English (en)
Inventor
Jacob J Plattner
Xianfeng Li
David Barros-Aguirre
Ilaria Giordano
Carlos Alemparte-Gallardo
M R K Alley (Dickon)
Vincent Hernandez
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55409879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002059(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd, Anacor Pharmaceuticals Inc filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of CL2017002059A1 publication Critical patent/CL2017002059A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>Se proporcionan benzoxaboroles sustituidos cuya estructura comprende la fórmula III: (Fórmula III) en donde R3 se selecciona a partir de –CH3 , –CH2CH3 , –CH2 =CH2 ,       –CH2C H2CH3 , –CH(CH3 ) 2 , – CH2C H2 =CH2 y ciclopropilo, R1 y R2 se seleccionan cada uno independientemente a partir de H,  - CH3 ,-C H2C H3 , –CH2C H2CH3 y –CH(CH3 ) 2 ; composiciones que contienen estos compuestos, su uso en terapia, incluyendo su uso como agentes anti-micobacterianos, por ejemplo, en el tratamiento de una infección micobacteriana en un mamífero, y los métodos para la preparación de estos compuestos.</p>
CL2017002059A 2015-02-12 2017-08-11 Compuestos 4- sustitutos de benzoxaborol y uso de los mismos CL2017002059A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382055 2015-02-12
EP15382056 2015-02-12
EP15382054 2015-02-12

Publications (1)

Publication Number Publication Date
CL2017002059A1 true CL2017002059A1 (es) 2018-03-16

Family

ID=55409879

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017002060A CL2017002060A1 (es) 2015-02-12 2017-08-11 Compuestos de benzoxaborol y usos de los mismos
CL2017002059A CL2017002059A1 (es) 2015-02-12 2017-08-11 Compuestos 4- sustitutos de benzoxaborol y uso de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017002060A CL2017002060A1 (es) 2015-02-12 2017-08-11 Compuestos de benzoxaborol y usos de los mismos

Country Status (36)

Country Link
US (3) US20180037595A1 (es)
EP (2) EP3256480A1 (es)
JP (2) JP2018506540A (es)
KR (2) KR20170117158A (es)
CN (2) CN107548398A (es)
AU (3) AU2016217508A1 (es)
BR (2) BR112017017211B1 (es)
CA (2) CA2976030C (es)
CL (2) CL2017002060A1 (es)
CO (2) CO2017008816A2 (es)
CR (2) CR20170371A (es)
CY (1) CY1123687T1 (es)
DK (1) DK3256479T3 (es)
DO (2) DOP2017000189A (es)
EA (2) EA036516B1 (es)
ES (1) ES2821951T3 (es)
HR (1) HRP20201597T1 (es)
HU (1) HUE051113T2 (es)
IL (2) IL253864B (es)
LT (1) LT3256479T (es)
MA (2) MA41495A (es)
MX (2) MX379057B (es)
MY (1) MY194004A (es)
NZ (1) NZ734379A (es)
PE (2) PE20171432A1 (es)
PH (2) PH12017501427A1 (es)
PL (1) PL3256479T3 (es)
PT (1) PT3256479T (es)
RS (1) RS60885B1 (es)
SG (2) SG11201706511TA (es)
SI (1) SI3256479T1 (es)
SM (1) SMT202000565T1 (es)
TW (2) TWI730953B (es)
UA (1) UA120527C2 (es)
WO (2) WO2016128949A1 (es)
ZA (1) ZA201705456B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160251380A1 (en) * 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
DK3621609T3 (da) 2017-05-08 2022-08-29 Glaxosmithkline Ip Dev Ltd Sanfetrinem eller et salt eller ester deraf til anvendelse i behandling af mykobakterieinfektion
MX2020005464A (es) 2017-11-30 2020-12-03 Boragen Inc Compuestos de benzoxaborol y formulaciones de los mismos.
EP3836938A4 (en) 2018-08-18 2022-05-11 Boragen, Inc. SOLID FORMS OF SUBSTITUTED BENZOXAZOLE AND COMPOSITIONS THEREOF
CN110441344B (zh) * 2019-06-25 2020-09-29 北京大学 一种基于固体核磁共振技术检测rna结构的方法
CA3239097A1 (en) 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Prodrugs of boron compounds and their use in treating bacterial infections
JP2025520237A (ja) * 2022-06-23 2025-07-03 ミクウルク ファーマシューティカルズ, インコーポレイテッド ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物
KR20240150582A (ko) 2023-04-08 2024-10-15 김태서 맥세이프 배터리팩을 포함한 아이폰 케이스

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
WO1998024753A1 (en) 1996-12-02 1998-06-11 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same
US7446236B2 (en) 2002-12-02 2008-11-04 Solvias Ag Catalytic hydrogenation of carbon-heteroatom double bonds
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
ES2872962T3 (es) 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
JP5084717B2 (ja) 2005-03-08 2012-11-28 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ キラル・ビスオキサゾリン触媒
TWM325238U (en) * 2006-12-29 2008-01-11 Universal Scient Ind Co Ltd Voltage regulator and voltage regulating system
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
SG172040A1 (en) 2008-12-17 2011-07-28 Anacor Pharmaceuticals Inc Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
AU2011237681B2 (en) * 2010-04-07 2015-01-22 Glaxosmithkline Llc Process for preparing benzoxaboroles
DK2613788T3 (en) 2010-09-07 2017-08-07 Anacor Pharmaceuticals Inc BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS
US8530452B2 (en) 2011-12-22 2013-09-10 Micurx Pharmaceuticals, Inc. Tricyclic boron compounds for antimicrobial therapy
CN102739587B (zh) 2012-06-16 2014-05-21 天地融科技股份有限公司 音频数据传输方法
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
US20160251380A1 (en) * 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof

Also Published As

Publication number Publication date
HRP20201597T1 (hr) 2020-12-25
CN107531730B (zh) 2020-08-07
EA201791667A1 (ru) 2018-02-28
HUE051113T2 (hu) 2021-01-28
US10774096B2 (en) 2020-09-15
NZ734379A (en) 2023-06-30
MY194004A (en) 2022-11-07
WO2016128948A1 (en) 2016-08-18
LT3256479T (lt) 2020-12-28
KR20170117156A (ko) 2017-10-20
SG11201706511TA (en) 2017-09-28
SMT202000565T1 (it) 2020-11-10
CY1123687T1 (el) 2022-03-24
TW201702250A (zh) 2017-01-16
CO2017008809A2 (es) 2017-11-10
PH12017501428A1 (en) 2018-01-15
CA2976308A1 (en) 2016-08-18
CO2017008816A2 (es) 2017-11-10
BR112017017211A2 (pt) 2018-04-03
JP2018506538A (ja) 2018-03-08
JP6771472B2 (ja) 2020-10-21
DOP2017000189A (es) 2018-02-15
MX2017010414A (es) 2018-05-11
IL253865A0 (en) 2017-10-31
KR20170117158A (ko) 2017-10-20
US11214582B2 (en) 2022-01-04
JP2018506540A (ja) 2018-03-08
TW201643173A (zh) 2016-12-16
PH12017501427A1 (en) 2018-01-15
MX379057B (es) 2025-03-10
US20180037595A1 (en) 2018-02-08
PT3256479T (pt) 2020-10-22
SI3256479T1 (sl) 2020-11-30
BR112017017211B1 (pt) 2023-04-25
MA41495A (fr) 2017-12-19
CA2976030C (en) 2023-09-26
PL3256479T3 (pl) 2021-06-14
EP3256480A1 (en) 2017-12-20
AU2016217508A1 (en) 2017-09-28
AU2020256369A1 (en) 2020-11-12
IL253864B (en) 2021-07-29
MX2017010413A (es) 2018-05-11
UA120527C2 (uk) 2019-12-26
AU2016217507B2 (en) 2019-03-14
EA201791671A1 (ru) 2018-02-28
WO2016128949A1 (en) 2016-08-18
CA2976030A1 (en) 2016-08-18
EP3256479A1 (en) 2017-12-20
TWI730953B (zh) 2021-06-21
MA41494B1 (fr) 2020-10-28
DK3256479T3 (da) 2020-11-02
MA41494A (fr) 2017-12-19
EP3256479B1 (en) 2020-07-29
US20210053996A1 (en) 2021-02-25
ZA201705456B (en) 2019-10-30
SG11201706510YA (en) 2017-09-28
BR112017017213A2 (pt) 2018-04-03
CR20170371A (es) 2018-01-22
IL253864A0 (en) 2017-09-28
RS60885B1 (sr) 2020-11-30
PE20171348A1 (es) 2017-09-13
DOP2017000188A (es) 2017-09-15
US20180044353A1 (en) 2018-02-15
PE20171432A1 (es) 2017-09-26
AU2016217507A1 (en) 2017-09-28
CN107531730A (zh) 2018-01-02
CR20170372A (es) 2017-10-19
CN107548398A (zh) 2018-01-05
ES2821951T3 (es) 2021-04-28
EA036516B1 (ru) 2020-11-18
CL2017002060A1 (es) 2018-03-16

Similar Documents

Publication Publication Date Title
CO2017008809A2 (es) Compuestos de benzoxaborol y uso de los mismos
CR20160064A (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CU20180144A7 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
PE20211782A1 (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
AR103251A1 (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
AR091285A1 (es) Inhibidores de bromodominio y sus usos
CU20170105A7 (es) Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
ECSP14004812A (es) Triazolopiridinas sustituidas
UY34388A (es) &#34;5,7-IMIDAZO[1,2-c]PIRIMIDINAS SUSTITUIDAS&#34;
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
ECSP13012596A (es) Proceso de elaboración para derivados de pirimidina
PE20170703A1 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos
UY36651A (es) Compuestos antiestrogénicos
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
AR093168A1 (es) COMPUESTOS DE OXAZOLIDINONA COMO INHIBIDORES DEL CANAL KCa3.1
UY36662A (es) Compuestos de benzoxaborol y uso de los mismos